Laboratory Investigation - Table of Contents alert Volume 89 Issue 4

LABORATORY INVESTIGATION

April 2009 Volume 89 Number 4, pp 372 - 484

--------------------------------------------------------------------------

You submitted your paper months ago. Still no answer?
Stop waiting and submit to Laboratory Investigation and receive a first
decision within 15 working days.

Our editorial office prides itself on fast efficient peer-review and
believes in a thorough, yet timely review of submitted papers.

Why submit?
- Impact factor of 4.479*
- Advanced Online Publication 31 days from paper acceptance
- Ranked in the top five of pathology journals

Read the Full Guide to Authors at:
http://links.ealert.nature.com/ctt?kn=42&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

--------------------------------------------------------------------------

Laboratory Investigation presents: Pathobiology in Focus

Innovative...Incisive...Thought-provoking

Pathobiology in Focus is a FREE and highly popular series on seminal advances
across the spectrum of disease pathogenesis, incorporating high-quality artwork
and powerpoint slides with concise articles. View the latest PIF online at
http://links.ealert.nature.com/ctt?kn=10&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

----------------------
INSIDE LAB INVEST
----------------------
Inside Lab Invest
http://links.ealert.nature.com/ctt?kn=6&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

----------------------
RESEARCH ARTICLES
----------------------
Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of
the mitochondrial permeability transition pore
Valery Leytin, David J Allen, Asuman Mutlu, Armen V Gyulkhandanyan, Sergiy Mykhaylov
and John Freedman
Abstract: http://links.ealert.nature.com/ctt?kn=33&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=17&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single
nucleotide polymorphism arrays
Thorsten Wiech, Elisabeth Nikolopoulos, Roland Weis, Rupert Langer, Kilian Bartholome,
Jens Timmer, Axel K Walch, Heinz Hofler and Martin Werner
Abstract: http://links.ealert.nature.com/ctt?kn=11&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=15&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Anaphylaxis to a self-peptide in the absence of mast cells or histamine
Silvia Musio, Paola Pedotti, Renato Mantegazza, Hiroshi Ohtsu, Louis Boon, Lawrence Steinman,
Stephen J Galli and Rosetta Pedotti
Abstract: http://links.ealert.nature.com/ctt?kn=44&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=28&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues
Isabelle Quadrio, Severine Ugnon-Cafe, Maryline Dupin, Guillaume Esposito, Nathalie Streichenberger,
Pierre Krolak-Salmon, Anne Vital, Jean-Francois Pellissier, Armand Perret-Liaudet and Herve Perron
Abstract: http://links.ealert.nature.com/ctt?kn=7&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=36&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Human peritoneal fibroblasts are a potent source of neutrophil-targeting cytokines: a key role of
IL-1[beta] stimulation
Janusz Witowski, Hironori Tayama, Krzysztof Ksiazek, Maria Wanic-Kossowska, Thorsten O Bender
and Achim Jorres
Abstract: http://links.ealert.nature.com/ctt?kn=35&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=30&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer
cell motility
Ken Yamazaki, Masaaki Takamura, Yohei Masugi, Taisuke Mori, Wenlin Du, Taizo Hibi,
Nobuyoshi Hiraoka, Tsutomu Ohta, Misao Ohki, Setsuo Hirohashi and Michiie Sakamoto
Abstract: http://links.ealert.nature.com/ctt?kn=52&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=53&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Both tacrolimus and sirolimus decrease Th1//Th2 ratio, and increase regulatory T
lymphocytes in the liver after ischemia//reperfusion
Javier Arias-Diaz, Jose A Ildefonso, Juan J Munoz, Agustin Zapata and Eva Jimenez
Abstract: http://links.ealert.nature.com/ctt?kn=34&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=27&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Involvement of CD44 in mast cell proliferation during terminal differentiation
Hirotsugu Takano, Shunsuke Nakazawa, Naritoshi Shirata, Shigero Tamba, Kazuyuki Furuta,
Sohken Tsuchiya, Kazushi Morimoto, Naoki Itano, Atsushi Irie, Atsushi Ichikawa,
Koji Kimata, Kazuhisa Nakayama, Yukihiko Sugimoto and Satoshi Tanaka
Abstract: http://links.ealert.nature.com/ctt?kn=40&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=31&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Morphological and functional heterogeneity of the mouse intrahepatic biliary epithelium
Shannon S Glaser, Eugenio Gaudio, Arundhati Rao, Lisa M Pierce, Paolo Onori, Antonio Franchitto,
Heather L Francis, David E Dostal, Julie K Venter, Sharon DeMorrow, Romina Mancinelli,
Guido Carpino, Domenico Alvaro, Shelley E Kopriva, Jennifer M Savage and Gianfranco D Alpini
Abstract: http://links.ealert.nature.com/ctt?kn=26&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=29&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts
established anti-GBM glomerulonephritis in the rat
Frank Y Ma, Robert S Flanc, Greg H Tesch, Brydon L Bennett, Glenn C Friedman and
David J Nikolic-Paterson
Abstract: http://links.ealert.nature.com/ctt?kn=2&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=14&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

--------------------------------------------------------------------------

This year, Modern Pathology makes its mark.

Modern Pathology is:

- One of the top two journals dedicated to general diagnostic anatomic
pathology
- The #6 journal in general pathology
- Now with an impact factor of 4.286

Innovative findings in clinical and translational research in the
pathology of human disease for over 20 years.
Visit Modern Pathology online at
http://links.ealert.nature.com/ctt?kn=4&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0

=====================================================================

You have been sent this Table of Contents Alert because you have opted in to receive it.
You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=19&m=32237826&r=MTc2Mjk0MzQ4MgS2&b=2&j=NDcwMDg4OTMS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department:
registration@nature.com

For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com

For other enquiries, please contact customer feedback department:
feedback@nature.com

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© Copyright 2009 Nature Publishing Group

=====================================================================

Nature Reviews Clinical Oncology - Table of Contents alert Volume 6 Issue 4

NATURE REVIEWS CLINICAL ONCOLOGY

April 2009 Volume 6 Number 4

Visit Nature Reviews Clinical Oncology online to browse the journal.

Now available at http://links.ealert.nature.com/ctt?kn=38&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Clinical Oncology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=45&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=64&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

*********************************************************************
Nature Reviews Clinical Oncology Impact Factor: 8.217*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************

=========================== ADVERTISEMENT ===========================

Nature Clinical Practice Oncology is now Nature Reviews Clinical
Oncology.

Nature Reviews Clinical Oncology brings the distinguished reputation
of the Nature Reviews series into the clinical sciences. The journal
will remain dedicated to publishing the latest advances in oncology.

For more information visit
http://links.ealert.nature.com/ctt?kn=36&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

=====================================================================

----------------------
EDITORIAL
----------------------
Off-label use of approved drugs
Vincent T. DeVita, Jr
p181 | doi:10.1038/nrclinonc.2009.41
http://links.ealert.nature.com/ctt?kn=32&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

----------------------
RESEARCH HIGHLIGHTS
----------------------
Surgery: Rotterdam Criteria is most important prognostic factor
p183 | doi:10.1038/nrclinonc.2009.10
http://links.ealert.nature.com/ctt?kn=21&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Hematology: Response to lenalidomide in myelodysplastic syndromes
p184 | doi:10.1038/nrclinonc.2009.12
http://links.ealert.nature.com/ctt?kn=83&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

LNR predicts rectal cancer survival
p184 | doi:10.1038/nrclinonc.2009.7
http://links.ealert.nature.com/ctt?kn=18&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Targeted therapies: Imatinib is not effective in uveal melanoma
p185 | doi:10.1038/nrclinonc.2009.11
http://links.ealert.nature.com/ctt?kn=30&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Genetics: Dicer and Drosha predict outcomes in ovarian cancer
p185 | doi:10.1038/nrclinonc.2009.5
http://links.ealert.nature.com/ctt?kn=35&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Hematology: Rituximab in follicular lymphoma
p186 | doi:10.1038/nrclinonc.2009.6
http://links.ealert.nature.com/ctt?kn=72&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Sorafenib for Asian-Pacific HCC
p186 | doi:10.1038/nrclinonc.2009.9
http://links.ealert.nature.com/ctt?kn=55&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

----------------------
NEWS AND VIEWS
----------------------
Screening: CT colonography: time for clinical implementation
Perry J. Pickhardt
p187 | doi:10.1038/nrclinonc.2009.20
The findings from a multicenter, screening trial of CT colonography for
the detection of large adenomas demonstrated the benefit of this
noninvasive technique for assessing patients with an average risk of
colorectal cancer.
http://links.ealert.nature.com/ctt?kn=22&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Hematology: Germinal center or nongerminal center DLBCL?
Gerhard Held and Michael Pfreundschuh
p188 | doi:10.1038/nrclinonc.2009.22
Patients with a immunohistochemically defined, germinal-center tumor
subtype have an improved outcome compared with patients with the
non-germinal-center phenotype when treated with CHOP only, according to
a prospective study. The benefit was not observed in those treated with
the rituximab combination therapy.
http://links.ealert.nature.com/ctt?kn=12&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Pathology: Are circulating tumor cells predictive of overall survival?
Klaus Pantel and Sabine Riethdorf
p190 | doi:10.1038/nrclinonc.2009.23
Comparison of circulating tumor cell numbers before and after treatment
is predictive for overall survival in patients with metastatic
castration-resistant prostate cancer; this comparison is more helpful
than prostate-specific antigen detection, according to a recent study.
http://links.ealert.nature.com/ctt?kn=68&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Medical oncology: Zoledronic acid prevents bone loss in early-stage breast
cancer
Francesco Bertoldo, Giuseppe Tonini, Bruno Vincenzi and Daniele Santini
p191 | doi:10.1038/nrclinonc.2009.24
Zoledronic acid is effective in the prevention of bone loss in premenopausal
women with breast cancer being treated with endocrine therapy. The benefit
of zoledronic acid probably extends for some years after cessation of
therapy.
http://links.ealert.nature.com/ctt?kn=65&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Surgery: Selective bladder-preserving therapy for muscle-invasive cancer
Niall M. Heney, Donald S Kaufman and William U. Shipley
p193 | doi:10.1038/nrclinonc.2009.21
Transurethral resection of the bladder and adjuvant chemoradiation can
permit eradication of the tumor and micrometastases. Close monitoring
by sequential cystoscopy and biopsy can achieve similar survival outcomes
to radical cystectomy, and could avoid invasive treatment.
http://links.ealert.nature.com/ctt?kn=6&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Surgery: Preserving continence in muscle-invasive bladder cancer
Anthony Costello and Rajiv Goel
p194 | doi:10.1038/nrclinonc.2009.26
Substantial progress has been made in radical cystectomy in the past 25
years, and development of orthotopic lower urinary tract reconstruction
has been an important step in the continued progress of urinary diversion.
The orthotopic neobladder should be considered the gold standard with
which other forms of diversion are compared.
http://links.ealert.nature.com/ctt?kn=84&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

----------------------
REVIEWS
----------------------
Is it time to consider a role for MRI before prostate biopsy?
Hashim U. Ahmed, Alex Kirkham, Manit Arya, Rowland Illing, Alex Freeman,
Clare Allen and Mark Emberton
p197 | doi:10.1038/nrclinonc.2009.18
The use of MRI for the management of prostate cancer is controversial;
however, technological advances in the past few years indicate that this
diagnostic approach should be utilized. The authors propose MRI could
improve risk stratification not only for those diagnosed with prostate
cancer but in men prior to a biopsy. They explain how MRI evaluation could
help select those men who require intervention and avoid biopsy and
unnecessary treatment in others.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=77&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Toxic effects and their management: daily clinical challenges in the
treatment of colorectal cancer
Cathy Eng
p207 | doi:10.1038/nrclinonc.2009.16
For patients with metastatic colorectal cancer, various treatment options
exist; however, all are associated with adverse events. Although the
majority of these adverse events are minor, some adverse effects might
be severe. This Review describes the toxic effects reported in key clinical
trials of biologic and cytotoxic agents. The author discusses the
strategies that can be implemented to manage toxicity and to minimize
treatment interruption or discontinuation, and enhance quality of life.
Abstract: http://links.ealert.nature.com/ctt?kn=52&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=5&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino, Salvatore Maria Corsello, Raffaele Longo, Agnese Barnabei
and Giampietro Gasparini
p219 | doi:10.1038/nrclinonc.2009.4
Targeted therapies such as tyrosine kinase inhibitors (TKI) have been
shown to induce hypothyroidism and thyroid dysfunction. The management
of thyroid dysfunction and possible related symptoms, such as fatigue,
represents a challenge to oncologists. The authors review the available
data of TKI-related thyroid dysfunction and propose a diagnostic and
therapeutic algorithm for the management of TKI-related hypothyroidism.
Abstract: http://links.ealert.nature.com/ctt?kn=39&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=44&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
Elizabeth R. Gerstner, Dan G. Duda, Emmanuelle di Tomaso, Peter A. Ryg,
Jay S. Loeffler, A. Gregory Sorensen, Percy Ivy, Rakesh K. Jain and
Tracy T. Batchelor
p229 | doi:10.1038/nrclinonc.2009.14
Most brain tumors secrete high levels of vascular endothelial growth factor,
which can lead to an abnormally permeable tumor vasculature. This
hyperpermeability causes vasogenic cerebral edema and increased interstitial
fluid pressure, which can prevent adequate penetration of chemotherapy
agents to the tumor. This Review focuses on the pathophysiology of
vasogenic edema and the potential utility of agents that target
angiogenesis, and particularly the vascular endothelial growth factor
pathway.
Abstract: http://links.ealert.nature.com/ctt?kn=23&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=70&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

----------------------
CASE STUDY
----------------------
Restoration of chemosensitivity by bortezomib: implications for refractory
myeloma
Chor Sang Chim, Yu Yan Hwang, Clara Pang and Tony W. Shek
p237 | doi:10.1038/nrclinonc.2009.15
Resistance to chemotherapy remains one of the major challenges in the
treatment of patients with multiple myeloma. Chim et al. report the case
of a 59-year-old woman with multiple myeloma, who progressed after treatment
with conventional chemotherapeutic agents. Addition of bortezomib to her
treatment regimen resulted in complete regression of her disease. The
authors suggest that bortezomib can restore chemosensitivity of myeloma
cells in heavily pretreated, chemorefractory patients with multiple myeloma.
Abstract: http://links.ealert.nature.com/ctt?kn=67&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=41&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

=========================== ADVERTISEMENT ===========================

Nature Collections Cancer

Cancer is driven by multiple genetic and epigenetic changes. This
collection highlights recent studies that catalogue these alterations
and shed light on the mechanisms by which cancer genes function.

Access the collection free online for 6 months and request a sample
copy at:
http://links.ealert.nature.com/ctt?kn=8&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0

Produced with support from Cephalon, Genentech, Boehringer Ingelheim
and Asterand

=====================================================================

You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=26&m=32237637&r=MTc2NDg2OTc4MQS2&b=2&j=NDcwMDc4MzES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department:
registration@nature.com

For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com

For other enquiries, please contact our customer feedback department:
feedback@nature.com

Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston

(c) Copyright 2009 Nature Publishing Group

=====================================================================

Cord Blood America: Congress Considers Tax Incentives for Storage

Release #:812-64738-em-434148:

Cord Blood America: Congress Considers Tax Incentives for Storage Cord Blood America Applauds Congressional Effort Supporting Cord Blood Storage SANTA MONICA, Calif., March 27 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it strongly supports the Family Cord Blood Banking Act introduced in the U.S. House of Representatives. The legislation will provide tax incentives for the medical expenses for those families choosing this potentially life-saving investment. It amends the Internal Revenue Code to add cord blood banking services as a qualified medical expense. "This would allow individuals and couples to pay for umbilical cord blood banking services through health savings accounts, flexible spending accounts, medical expenses tax deduction and health reimbursement arrangements," said Matthew Schissler, CEO and Founder, Cord Blood America. The legislation was introduced by Representatives Wally Herger (R-CA.), Rep. Ron Kind (D-WI), Mike Thompson (D-CA), Artur Davis (D-AL), and Bill Pascrell Jr. (D-NJ). The Congressmen in a press statement said "umbilical cord blood stem cells have been used in more than 14,000 transplants around the world and to treat more than 70 diseases in adults and children. The legislation could make this storage an option for more families facing potentially life-threatening diseases, increase the supply of cord blood stem cells and lower the costs for families in the future." About Cord Blood America Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.   Paul Knopick E & E Communications pknopick@eandecommunications.com 949/707-5365

My EANDE More Information

Signaling Update contents for 27 March 2009

*********************************************************************
Signaling Gateway - 27 March 2009
http://links.ealert.nature.com/ctt?kn=33&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0
*********************************************************************

Signaling Update is a one-stop online resource designed to keep you
in touch with the latest and most exciting research in cell
signaling. New content is uploaded every Friday.

*********************************************************************
In Signaling Update this week:

------------------------
Featured Article
------------------------
MEK KINASES: DIMERS DIM MAPK SIGNALING

Mek1-Mek2 heterodimer formation is essential for Erk-mediated
attenuation of the Raf-Mek-Erk signaling cascade.

Original research paper: Nature Structural & Molecular Biology 16,
294-303 (2009)

http://links.ealert.nature.com/ctt?kn=27&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

------------------------
Molecule Pages
------------------------
VILIP-1
http://links.ealert.nature.com/ctt?kn=3&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

Visinin-like protein 1 (VILIP-1) belongs to a highly homologous
subfamily of neuronal Ca2+ sensor (NCS) proteins. VILIP-1 is
expressed predominantly in the brain, but lower levels of expression
are found in peripheral organs and in several cancer types, where
the protein exhibits a suppressive function for tumor invasion.
Interestingly, VILIP-1 expression is downregulated in several
neurodegenerative diseases, such as Alzheimer's disease, stroke,
spinal cord injury and amyotrophic lateral sclerosis (ALS).

Also published this week: Rab11a
http://links.ealert.nature.com/ctt?kn=25&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

Search the molecule pages
http://links.ealert.nature.com/ctt?kn=34&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

-------------------
Selected Updates
-------------------
MECHANOTRANSDUCTION: SWITCH AND STRETCH
Two papers provide new insights into the mechanism underlying the
mechanoresponsive activation of alpha5beta1 integrin, as well as the
basis for the interaction between the force-bearing cytoskeleton
protein talin and its binding partner vinculin.
Original research paper: Science 323, 638–641 (2009)
http://links.ealert.nature.com/ctt?kn=24&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

GENETICS: NETWORKING ON THE FLY
Analysis of gene networks in Drosophila can be an effective method
for identifying new genes that are deregulated in human disease.
Original research paper: Science 323, 1218-1222 (2009)
http://links.ealert.nature.com/ctt?kn=29&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

OBESITY: REVERSING LEPTIN RESISTANCE
Decreasing endoplasmic reticulum (ER) stress may sensitize the body
to the key metabolic regulator leptin, revealing a potential
therapeutic strategy for obesity.
Original research paper: Cell Metab. 9, 35–51 (2009)
http://links.ealert.nature.com/ctt?kn=15&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

More Updates:
http://links.ealert.nature.com/ctt?kn=11&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

------------------------
Research Library
------------------------
INTERCELLULAR TRANSFER TO SIGNALLING ENDOSOMES REGULATES AN EX VIVO
BONE MARROW NICHE
Nature Cell Biology 11, 303–311 (2009)
http://links.ealert.nature.com/ctt?kn=30&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

INFLUENCE OF CRACC, A SLAM FAMILY RECEPTOR COUPLED TO THE ADAPTOR
EAT-2, ON NATURAL KILLER CELL FUNCTION
Nature Immunology 10, 297–305 (2009)
http://links.ealert.nature.com/ctt?kn=21&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

NEUROPROTECTIVE EFFECTS OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN
RODENT AND PRIMATE MODELS OF ALZHEIMER'S DISEASE
Nature Medicine 15, 331–337 (2009)
http://links.ealert.nature.com/ctt?kn=35&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

------------------------
Signaling News
------------------------
PROMISCUOUS ANTIBODY TARGETS CANCER
http://links.ealert.nature.com/ctt?kn=12&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

A report in Science describes an engineered antibody that can
interact simultaneously with vascular endothelial growth factor
(VEGF) and human epidermal growth factor receptor 2 (HER2).
The antibody blocked HER2- and VEGF-mediated cellular proliferation
and slowed tumor progression in mice, suggesting that it could be a
novel means to achieve dual-targeting therapy in cancer.

More news
http://links.ealert.nature.com/ctt?kn=10&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

-------------------------
Gateway Updates
-------------------------
THE FUNCTIONAL GLYCOMICS GATEWAY - MARCH UPDATE
http://links.ealert.nature.com/ctt?kn=20&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

The Functional Glycomics Gateway is a comprehensive FREE online
resource to keep you abreast of the latest findings in the field.

This month's update features:
Targeted protein transport: Show your sugar pass
http://links.ealert.nature.com/ctt?kn=18&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

Lung metastasis: Novel carbohydrate receptors open the door
http://links.ealert.nature.com/ctt?kn=31&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

Sign up to receive the monthly table of contents e-alert for the
Functional Glycomics Update.
http://links.ealert.nature.com/ctt?kn=28&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

-----------------------------
Job of the Week
-----------------------------
Postdoctoral fellow
Employer: Jersey Medical School
Location: Newark, New Jersey, USA
http://links.ealert.nature.com/ctt?kn=8&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

A postdoctoral position is available in the newly opened Cancer
Center at the New Jersey Medical School to investigate how genetic
alterations in oncogenic and tumor suppressor signaling pathways
impact normal development and cancer. The successful applicant will
use tissue culture systems and mouse models to delineate various
signaling networks in the hematopoietic system, and prostate and
mammary glands.

More Jobs:
http://links.ealert.nature.com/ctt?kn=9&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

To advertise a job in this spot, please contact Naturejobs.
http://links.ealert.nature.com/ctt?kn=22&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

======================================================================

Genentech is proud to be a corporate sponsor of the UCSD-Nature Signaling Gateway.

Genentech is a leading biotechnology company that discovers,
develops, manufactures and commercializes biotherapeutics
for significant unmet medical needs. Fifteen of the currently
approved biotechnology products stem from or are based on
Genentech science. Genentech manufactures and commercializes
ten biotechnology products directly in the United States.
The company has headquarters in South San Francisco, California,
and is traded on the New York Stock Exchange under the symbol DNA.

http://links.ealert.nature.com/ctt?kn=5&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0
=====================================================================
As a registered user of the Nature Publishing Group web sites, you
were selected to receive this message in the genuine belief that it
would be of interest to you.

If you no longer wish to receive news and announcements from Nature
Publishing Group or wish to unsubscribe from the Signaling Update
email alert please update your online Nature.com account details here:
http://links.ealert.nature.com/ctt?kn=32&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

For further technical assistance or any other enquiries, please click here:
http://links.ealert.nature.com/ctt?kn=1&m=32210333&r=MTc2ODc4NDI0MAS2&b=2&j=NDY5MTExNTIS1&mt=1&rt=0

Nature's world-wide offices:
London . Paris . Munich . New Delhi . Tokyo . Melbourne . San Diego .
San Francisco . Washington . New York . Boston

(c) 2009 Nature Publishing Group
---------------------------------------------------------------------

Nature Reviews Cardiology - Table of Contents alert Volume 6 Issue 4

NATURE REVIEWS CARDIOLOGY

April 2009 Volume 6 Number 4

Visit Nature Reviews Cardiology online to browse the journal.

Now available at http://links.ealert.nature.com/ctt?kn=12&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Cardiology online. To purchase a subscription, please
visit:
http://links.ealert.nature.com/ctt?kn=45&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=66&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

*********************************************************************
Nature Reviews Cardiology Impact Factor: 4.743*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************

=========================== ADVERTISEMENT ===========================

Introducing: Nature Reviews Cardiology
http://links.ealert.nature.com/ctt?kn=35&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Nature Clinical Practice Cardiovascular Medicine is now Nature Reviews
Cardiology. With an improved website and additional content, Nature
Reviews Cardiology brings all the qualities of the top-ranked life
sciences series to the clinical sciences. Visit Nature Reviews
Cardiology online to experience the clinical sciences through Nature
Reviews.
http://links.ealert.nature.com/ctt?kn=35&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

=====================================================================

----------------------
RESEARCH HIGHLIGHTS
----------------------
Surgery: Insights into patients' outcomes after the Ross procedure
p263 | doi:10.1038/nrcardio.2009.15
http://links.ealert.nature.com/ctt?kn=14&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Stress-related behavior and CVD
p264 | doi:10.1038/nrcardio.2009.16
http://links.ealert.nature.com/ctt?kn=7&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Hypertension: Aliskerin outshines diuretic
p264 | doi:10.1038/nrcardio.2009.21
http://links.ealert.nature.com/ctt?kn=52&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Arrhythmias: Catheter ablation can prevent VT
p265 | doi:10.1038/nrcardio.2009.17
http://links.ealert.nature.com/ctt?kn=63&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Acute coronary syndromes: Prehospital ECG improves outcome in STEMI
p265 | doi:10.1038/nrcardio.2009.19
http://links.ealert.nature.com/ctt?kn=74&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

PAD patients walk to better health
p265 | doi:10.1038/nrcardio.2009.20
http://links.ealert.nature.com/ctt?kn=87&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Hypertension: A new marker of irreversible PAH
p266 | doi:10.1038/nrcardio.2009.18
http://links.ealert.nature.com/ctt?kn=76&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Coronary artery disease: Measuring FFR improves success of PCI
p266 | doi:10.1038/nrcardio.2009.22
http://links.ealert.nature.com/ctt?kn=25&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

----------------------
NEWS AND VIEWS
----------------------
Interventional cardiology: Coronary angioplasty: do we need to EuroSCORE?
Scot Garg and Patrick W. Serruys
p267 | doi:10.1038/nrcardio.2009.27
An effective risk score for patients undergoing coronary angioplasty is
yet to be established. In this article we discuss the merits of using the
EuroSCORE risk model for assessing these patients, and propose a potential
modification to the system.
http://links.ealert.nature.com/ctt?kn=41&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Cardiomyopathies: The fatty hearts of patients with diabetes
Ildiko Lingvay, Philip Raskin and Lidia S. Szczepaniak
p268 | doi:10.1038/nrcardio.2009.30
Magnetic Resonance Spectroscopy is a novel research tool used to
noninvasively quantify myocardial triglyceride content. This method provides
the opportunity to study myocardial steatosis in patients with diabetes.
http://links.ealert.nature.com/ctt?kn=26&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Hypertension: Combination therapy for hypertension
Norman M. Kaplan
p270 | doi:10.1038/nrcardio.2009.31
Two or more drugs are needed to control blood pressure in the majority of
patients with hypertension. The most commonly used combinations include a
diuretic; however, results of two large, controlled trials show that better
cardiovascular protection is provided by a combination of a renin-angiotensin
inhibitor and a long-acting calcium-channel blocker than combinations that
include a diuretic.
http://links.ealert.nature.com/ctt?kn=50&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Antiplatelet therapy: The P2Y12 receptor: no active metabolite, no party
Carlo Patrono
p271 | doi:10.1038/nrcardio.2009.29
Poor responders to clopidogrel have low levels of circulating active
metabolite. However, in vitro experiments have shown that blood platelets
from poor responders are fully inhibited by the active metabolite of this
prodrug. Impaired platelet inhibition reflects inadequate plasma levels of
active metabolites, and not differences in platelet P2Y12 receptor function.
http://links.ealert.nature.com/ctt?kn=55&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

----------------------
REVIEWS
----------------------
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements
Joseph M. Sweeny, Diana A. Gorog and Valentin Fuster
p273 | doi:10.1038/nrcardio.2009.10
In the first section of this two-part Review, Dr Sweeny and colleagues
explore the phenomenon of 'resistance' to antiplatelet drug therapy. They
discuss the various factors influencing the patient's response to these
drugs, and examine the link between laboratory-assessed nonresposiveness and
clinical outcome.
Abstract: http://links.ealert.nature.com/ctt?kn=19&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Novel pharmacotherapies to abrogate postinfarction ventricular remodeling
Gerald W. Dorn II
p283 | doi:10.1038/nrcardio.2009.12
Ventricular remodeling occurs over the weeks and months after myocardial
infarction, and, therefore, provides a large temporal therapeutic window.
In this Review, Dr Dorn examines recent developments in pharmacological
treatment of ventricular remodeling in preclinical models of myocardial
infarction.
Abstract: http://links.ealert.nature.com/ctt?kn=5&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=81&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Mechanisms by which exercise training benefits patients with heart failure
Ettore Crimi, Louis J. Ignarro, Francesco Cacciatore and Claudio Napoli
p292 | doi:10.1038/nrcardio.2009.8
Current treatment guidelines recommend exercise training in patients with
heart failure classified as NYHA functional class II and III. This Review
focuses on current knowledge of mechanisms by which progressive and moderate
exercise training can have sustained beneficial effects on these patients.
Abstract: http://links.ealert.nature.com/ctt?kn=62&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=34&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

Cardiovascular implications of proteinuria: an indicator of chronic kidney
disease
Varun Agrawal, Victor Marinescu, Mohit Agarwal and Peter A. McCullough
p301 | doi:10.1038/nrcardio.2009.11
Proteinuria often precedes any detectable decline in renal filtration
function and is a strong and independent predictor of increased risk for
all-cause and cardiovascular mortality. In this Review, Dr Agrawal and
colleagues examine potential pathophysiologic mechanisms to explain
simultaneous renal and cardiac disease, as well as therapeutic strategies
for amelioration of proteinuria.
Abstract: http://links.ealert.nature.com/ctt?kn=47&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=11&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

----------------------
CASE STUDY
----------------------
Provokable left ventricular outflow tract obstruction in a patient without
hypertrophy
Ferdinando Pasquale, Maria Teresa Tome-Esteban, Riccardo Morgagni and
Perry Elliott
p313 | doi:10.1038/nrcardio.2009.7
Dr Pasquale and colleagues demonstrate that dynamic left ventricular
outflow tract obstruction was the cause of exertional chest pain and
dyspnea in a patient with no evidence of hypertrophic cardiomyopathy or
ischemic heart disease.
Abstract: http://links.ealert.nature.com/ctt?kn=10&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=84&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

----------------------
PERSPECTIVES
----------------------
OPINION
Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying
hypothesis
Iacopo Olivotto, Franco Cecchi, Corrado Poggesi and Magdi H. Yacoub
p317 | doi:10.1038/nrcardio.2009.9
In this fascinating Perspective article, the authors propose a novel
hypothesis for the developmental origin of the variable phenotypes seen
in hypertrophic cardiomyopathy (HCM). They suggest that cross-talk between
healthy epicardium-derived cells and abnormally contracting cardiomyocytes
could account for the extramyocardial manifestations of HCM, by a putative
mechanism of mechanotransduction leading to abnormal gene expression and
cell differentiation.
Abstract: http://links.ealert.nature.com/ctt?kn=56&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=42&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

=========================== ADVERTISEMENT ===========================

Nature Reviews Cardiology - key scientific developments in cardiology
from a distinguished series.

Ensure your access.

If you are unable to access the articles in this Table of Contents
e-alert, your library may not subscribe to this journal. Our online
recommendation form is a simple way to make your librarian aware that
Nature Reviews Cardiology is valuable to your research.

Recommend now at
http://links.ealert.nature.com/ctt?kn=66&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0

=====================================================================

You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=27&m=32199957&r=MTc2NDI1MzEzNAS2&b=2&j=NDY4OTE1NDcS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department:
registration@nature.com

For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com

For other enquiries, please contact our customer feedback department:
feedback@nature.com

Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston

(c) Copyright 2009 Nature Publishing Group

=====================================================================

Nature Reviews Nephrology - Table of Contents alert Volume 5 Isssue 4

NATURE REVIEWS NEPHROLOGY

April 2009 Volume 5 Number 4

Visit Nature Reviews Nephrology online to browse the journal.

Now available at http://links.ealert.nature.com/ctt?kn=27&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Nephrology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=41&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=65&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

*********************************************************************
Nature Reviews Nephrology Impact Factor: 4.764*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************

=========================== ADVERTISEMENT ===========================

WCN 2009 World Congress of Nephrology
Milan, May 22 - 26

http://links.ealert.nature.com/ctt?kn=25&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

=====================================================================

=========================== ADVERTISEMENT ===========================

Nature Clinical Practice Nephrology is now Nature Reviews Nephrology.

Nature Reviews Nephrology brings the distinguished reputation of the
Nature Reviews series into the clinical sciences. The journal will remain
dedicated to publishing the latest clinical advances in nephrology.

For more information visit
http://links.ealert.nature.com/ctt?kn=13&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

=====================================================================

----------------------
EDITORIAL
----------------------
Presumed consent: yes we should
Chloe Harman
p177 | doi:10.1038/nrneph.2009.47
http://links.ealert.nature.com/ctt?kn=12&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

----------------------
RESEARCH HIGHLIGHTS
----------------------
Chronic kidney disease: Reduced benefit of coronary interventions in
chronic kidney disease
p179 | doi:10.1038/nrneph.2009.18
http://links.ealert.nature.com/ctt?kn=61&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Transplantation: A simple test for PVN
p180 | doi:10.1038/nrneph.2009.19
http://links.ealert.nature.com/ctt?kn=6&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Phosphate binders 'effective' in PD
p180 | doi:10.1038/nrneph.2009.22
http://links.ealert.nature.com/ctt?kn=42&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Fatty acids for IgA nephropathy
p181 | doi:10.1038/nrneph.2009.20
http://links.ealert.nature.com/ctt?kn=70&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Transplantation: Bortezomib treats renal graft rejection
p181 | doi:10.1038/nrneph.2009.7
http://links.ealert.nature.com/ctt?kn=29&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Development: Insect nephrocytes resemble human podocytes
p181 | doi:10.1038/nrneph.2009.9
http://links.ealert.nature.com/ctt?kn=17&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Transplantation: Reassuring news for kidney donors
p182 | doi:10.1038/nrneph.2009.21
http://links.ealert.nature.com/ctt?kn=44&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Diabetes: Could vitamin 'B' the answer?
p182 | doi:10.1038/nrneph.2009.8
http://links.ealert.nature.com/ctt?kn=51&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

----------------------
NEWS AND VIEWS
----------------------
Hypertension: An ACCOMPLISHED regimen for hypertension
Fiona Turnbull
p183 | doi:10.1038/nrneph.2009.25
At first glance, the findings of the ACCOMPLISH trial threaten to undermine
the importance of diureticss in the arsenal of blood-pressure-lowering
therapies. But closer examination reveals that the story is more complicated.
http://links.ealert.nature.com/ctt?kn=80&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Acute kidney injury: Clinical value of urine microscopy in acute kidney
injury
Sean M. Bagshaw and R. T. Noel Gibney
p185 | doi:10.1038/nrneph.2009.23
Urine microscopy is a time-honored, readily available and commonly used
noninvasive test to aid clinicians in discriminating between different
forms of acute kidney injury. However, the diagnostic and prognostic
importance of assessing urinary sediment is largely unknown.
http://links.ealert.nature.com/ctt?kn=48&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Thrombotic microangiopathy: What not to learn from a meta-analysis
Marina Noris and Giuseppe Remuzzi
p186 | doi:10.1038/nrneph.2009.28
A recent meta-analysis concluded that plasma exchange is the most
effective intervention for thrombotic thrombocytopenic purpura and that
plasma manipulation offers no additional benefit over simple supportive
therapy in hemolytic uremic syndrome. These findings must be interpreted
with great caution, as response to treatment depends on the underlying
disease etiology.
http://links.ealert.nature.com/ctt?kn=5&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Hypertension: The message of World Kidney Day 2009
George L. Bakris and Eberhard Ritz and on behalf of the World Kidney
Day Steering Committee
p188 | doi:10.1038/nrneph.2009.27
World Kidney Day 2009 was celebrated last month in more than 100
countries, and aimed to raise awareness that the symbiotic
relationship between hypertension and kidney disease should be prevented.
http://links.ealert.nature.com/ctt?kn=22&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Transplantation: Neural networks for predicting graft survival
Bruce Kaplan and Jesse Schold
p190 | doi:10.1038/nrneph.2009.24
Predicting outcomes of renal transplant recipients using standard
statistical techniques is difficult. Novel approaches such as the use
of artificial neural networks might improve the precision and accuracy
in this area of medicine in which numerous and complex events contribute
to outcomes.
http://links.ealert.nature.com/ctt?kn=91&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

----------------------
REVIEWS
----------------------
Fluid, electrolyte and acid-base disorders associated with antibiotic
therapy
R. Zietse, R. Zoutendijk and E. J. Hoorn
p193 | doi:10.1038/nrneph.2009.17
Antibiotic treatment can lead to a wide spectrum of disturbances in the
electrolyte and/or acid-base balance, despite a preserved glomerular
filtration rate. This Review describes how each nephron segment is
affected by antibiotic treatment and discusses the mechanisms that lead
to disrupted renal tubular function. This insight should pave the way
for pathophysiology-directed treatment of these disorders.
Abstract: http://links.ealert.nature.com/ctt?kn=45&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=75&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

The role of plasminogen activator inhibitor 1 in renal and cardiovascular
diseases
Hunjoo Ha, Eun Y. Oh and Hi B. Lee
p203 | doi:10.1038/nrneph.2009.15
An orally active small-molecule inhibitor of plasminogen activator
inhibitor 1 (PAI-1) could provide a novel therapeutic strategy for renal
and cardiovascular diseases. Here, authors from Ewha Womans University,
Seoul review current understanding of the role of PAI-1 in renal fibrosis
and intimal hyperplasia, with a particular focus on the regulation of
PAI-1 expression by reactive oxygen species. They also discuss the
progress that has been made toward achieving therapeutic suppression
of PAI-1.
Abstract: http://links.ealert.nature.com/ctt?kn=89&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=1&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Membranous nephropathy in systemic lupus erythematosus: a therapeutic
enigma
Chi Chiu Mok
p212 | doi:10.1038/nrneph.2009.14
Membranous nephropathy is an uncommon form of lupus nephritis, accounting
for only one-fifth of all cases. As a result, few reviews have focused
on this condition. Here, Chi Chiu Mok summarizes the histological
classification, clinical presentation, outcomes and therapy of membranous
lupus nephropathy. As the optimal therapy for this form of lupus nephritis
remains unclear, the author provides an algorithm to help guide treatment.
Abstract: http://links.ealert.nature.com/ctt?kn=18&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=77&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Cardiovascular abnormalities in autosomal-dominant polycystic kidney
disease
Tevfik Ecder and Robert W. Schrier
p221 | doi:10.1038/nrneph.2009.13
This Review describes the cardiovascular manifestations of
autosomal-dominant polycystic kidney disease (ADPKD), including
hypertension, left ventricular hypertrophy, aneurysms and cardiac valvular
disorders. The authors focus particularly on hypertension, with a detailed
discussion of the pathogenesis of this condition in ADPKD and a
comprehensive review of the renal and cardiovascular effects of
antihypertensive treatment in the ADPKD setting. Recommendations for the
optimal cardiovascular management of ADPKD are provided.
Abstract: http://links.ealert.nature.com/ctt?kn=82&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=74&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

Cardiovascular disease in children with CKD or ESRD
Marc R. Lilien and Jaap W. Groothoff
p229 | doi:10.1038/nrneph.2009.10
Children with end-stage renal disease (ESRD) have a more than 700-fold
increased risk of cardiac death compared with healthy children of the
same age. Here, pediatric nephrologists from the Netherlands describe
the arterial and cardiac abnormalities that are responsible for this
high cardiovascular burden, outline the risk factors for such abnormalities,
and suggest strategies for their prevention. The need for prospective
follow-up studies of cardiac risk factors in the pediatric ESRD setting
is highlighted.
Abstract: http://links.ealert.nature.com/ctt?kn=53&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=46&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

----------------------
CASE STUDY
----------------------
Focal segmental glomerulosclerosis as a complication of graft-versus-host
disease
Claudia Fofi, Simona Barberi, Antonella Stoppacciaro, Giorgio Punzo and
Paolo Mene
p236 | doi:10.1038/nrneph.2009.11
Kidney involvement can be a serious complication of hematopoietic stem
cell transplantation. In this Case Study, Fofi and colleagues describe
a rare case of focal segmental glomerulosclerosis occurring as a
complication of chronic graft-versus-host disease following peripheral
blood stem cell transplantation.
Abstract: http://links.ealert.nature.com/ctt?kn=85&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=83&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

=========================== ADVERTISEMENT ===========================

This year, Modern Pathology makes its mark.

Modern Pathology is:

- One of the top two journals dedicated to general diagnostic anatomic
pathology
- The #6 journal in general pathology
- Now with an impact factor of 4.286

Innovative findings in clinical and translational research in the pathology
of human disease for over 20 years. Visit Modern Pathology online at
http://links.ealert.nature.com/ctt?kn=73&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0

=====================================================================

You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=30&m=32199035&r=MTc2NDE4ODIzOQS2&b=2&j=NDY4ODg2NzMS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department:
registration@nature.com

For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com

For other enquiries, please contact our customer feedback department:
feedback@nature.com

Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston

(c) Copyright 2009 Nature Publishing Group

=====================================================================

physics@nature.com 26 March 2009

*********************************
physics@nature.com
*********************************

WOULD YOU PREFER TO RECEIVE THIS ALERT IN HTML FORMAT?
Tell us at http://links.ealert.nature.com/ctt?kn=39&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

*********************************************************************
Bringing you the latest and best in physics news and research from
Nature Publishing Group

For more information, see each journal's latest table of contents:

Nature Volume 458 Number 7237 pp 385-542
http://links.ealert.nature.com/ctt?kn=77&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Nature Physics Volume 5 Number 3 pp 161-235
http://links.ealert.nature.com/ctt?kn=96&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Nature Materials Volume 8 Number 3 pp 161-242
http://links.ealert.nature.com/ctt?kn=2&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Nature Nanotechnology Volume 4 Number 3 pp 135-201
http://links.ealert.nature.com/ctt?kn=50&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Nature Photonics Volume 3 Number 3 pp 117-176
http://links.ealert.nature.com/ctt?kn=71&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

======================================================================

Nature Photonics Technology Focus
Qualify today for your FREE subscription!

Each Technology Focus contains a unique mix of industry-related
articles that cover important emerging applications, the latest
business news, product releases and research papers in the field.

Qualify below to get your free subscription.
http://links.ealert.nature.com/ctt?kn=118&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

======================================================================

-------------------------------
Editorial
-------------------------------

A cut too far
http://links.ealert.nature.com/ctt?kn=113&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

-------------------------------
News
-------------------------------

Graphene gets ready for the big time
http://links.ealert.nature.com/ctt?kn=13&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

UK funding ban sparks protests
http://links.ealert.nature.com/ctt?kn=59&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Canadian science minister under fire
http://links.ealert.nature.com/ctt?kn=69&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

-------------------------------
News in Brief
-------------------------------

Science head of energy department is named
http://links.ealert.nature.com/ctt?kn=115&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

-------------------------------
News Features
-------------------------------

The rock that fell to Earth
http://links.ealert.nature.com/ctt?kn=54&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

-------------------------------
Books and Arts
-------------------------------

New technologies, same old politics
http://links.ealert.nature.com/ctt?kn=49&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Science for the greater economic good
http://links.ealert.nature.com/ctt?kn=19&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Bringing clarity to complexity
http://links.ealert.nature.com/ctt?kn=60&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

-------------------------------
News and Views
-------------------------------

Astrophysics: Quiet is the new loud
http://links.ealert.nature.com/ctt?kn=4&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

-------------------------------
Letters
-------------------------------

Accretion disk winds as the jet suppression mechanism in the
microquasar GRS 19151+105
Joseph Neilsen & Julia C. Lee
http://links.ealert.nature.com/ctt?kn=67&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Electromotive force and huge magnetoresistance in magnetic
tunnel junctions
Pham Nam Hai, Shinobu Ohya, Masaaki Tanaka, Stewart E. Barnes
& Sadamichi Maekawa
http://links.ealert.nature.com/ctt?kn=74&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

The quantum-optical Josephson interferometer
Dario Gerace, Hakan E. Türeci, Atac Imamoglu, Vittorio Giovannetti
& Rosario Fazio
http://links.ealert.nature.com/ctt?kn=119&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Impulsive orientation and alignment of quantum-state-selected
NO molecules
Omair Ghafur et al.
http://links.ealert.nature.com/ctt?kn=132&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Ultrafast optical rotations of electron spins in quantum dots
A. Greilich et al.
http://links.ealert.nature.com/ctt?kn=56&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Tightly trapped acoustic phonons in photonic crystal fibres as
highly nonlinear artificial Raman oscillators
M. S. Kang, A. Nazarkin, A. Brenn & P. St. J. Russell
http://links.ealert.nature.com/ctt?kn=112&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Polychromatic dynamic localization in curved photonic lattices
Alexander Szameit et al.
http://links.ealert.nature.com/ctt?kn=70&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Tunnelling readout of hydrogen-bonding-based recognition
Shuai Chang et al.
http://links.ealert.nature.com/ctt?kn=52&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

An electric current spike linked to nanoscale plasticity
Roman Nowak et al.
http://links.ealert.nature.com/ctt?kn=125&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Imaging through nonlinear media using digital holography
Christopher Barsi, Wenjie Wan & Jason W. Fleischer
http://links.ealert.nature.com/ctt?kn=10&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

Green light emission in silicon through slow-light enhanced
third-harmonic generation in photonic-crystal waveguides
B. Corcoran et al.
http://links.ealert.nature.com/ctt?kn=108&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

-------------------------------
Articles
-------------------------------

Heat-assisted magnetic recording by a near-field transducer with
efficient optical energy transfer
W. A. Challener et al.
http://links.ealert.nature.com/ctt?kn=46&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

A gigahertz-bandwidth atomic probe based on the slow-light
Faraday effect
Paul Siddons, Nia C. Bell, Yifei Cai, Charles S. Adams
& Ifan G. Hughes
http://links.ealert.nature.com/ctt?kn=28&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

=====================================================================

Subscribe to Nature Photonics, providing a unique forum for all
aspects of photonics and optoelectronics.
http://links.ealert.nature.com/ctt?kn=111&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0

=====================================================================

You have been sent this Table of Contents Alert because you have
opted in to receive it. You can change or discontinue your e-mail
alerts at any time, by modifying your preferences on your
nature.com account at: http://links.ealert.nature.com/ctt?kn=58&m=32198635&r=MTc2ODM1MzAwNQS2&b=2&j=NDY4ODgzNDES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration
department: mailto:registration@nature.com

For print subscription enquiries, please contact our subscription
department: mailto:subscriptions@nature.com

For other enquiries, please contact our customer feedback department:
mailto:feedback@nature.com

Nature Publishing Group * 75 Varick Street, 9th floor * New York *
NY 10013-1917 * USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Copyright 2008 Nature Publishing Group

=====================================================================